D-0003-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0003-2021 was initiated by Teva Pharmaceuticals USA on Sep 4, 2020 and is designated Class II. Reason for recall: Failed Stability Specifications: Below specification result for buprenorphine release rate. The recall status is terminated (terminated Aug 26, 2021). Affected quantity: 32,543 cartons.

Recall details

Product Type
Drugs
Report Date
Oct 7, 2020
Initiation Date
Sep 4, 2020
Termination Date
Aug 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
32,543 cartons

Product description

Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only, Manufactured by: 3M Drug Delivery Systems, 19901 Nordhoff street, Northridge, CA 91324 USA, Manufactured for: Teva Pharmaceuticals USA Inc., North Wales, PA 19454, carton NDC: 0093-3656-40, patch NDC: 0093-3656-21.

Reason for recall

Failed Stability Specifications: Below specification result for buprenorphine release rate.

Distribution pattern

Nationwide in the U.S. and PR

Code information

Lot # 190017, exp. 02/2021; 190161, exp. 08/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0003-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0003-2021. Report a data issue: hello@regdatalab.com.